44 results
424B5
NLSP
NLS Pharmaceutics Ltd
22 Mar 24
Prospectus supplement for primary offering
10:24am
of the next generation of CNS therapies with high medical impact to address this critical and growing unmet need. Our dual development strategy … unmet need. Our dual development strategy is designed to optimize the outcome of our clinical programs by developing new chemical entities from known
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
total future research and development costs will increase over current levels in line with strategy to progress the development of our product
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
4 Dec 23
Report of Foreign Private Issuer
4:00pm
creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.
With AUDACIA and ALOE Private equity
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
13 Sep 23
Report of Foreign Private Issuer
4:03pm
of Scientific Excellence Jeff Bernier Head of Clinical Operations Sharon Tan, MBA Head of Program Management & Strategy Bao Le, MS Head of Regulatory Experienced
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
20 Jul 23
Report of Foreign Private Issuer
4:06pm
Operations Sharon Tan, MBA Program Management & Strategy Bao Le, MS Regulatory Affairs Experienced Team Assembled Andreas Fischer Supply Chain Sam Salamone … Materials Launch Anticipation Communications Market Access Pricing and Contracting Strategy Payer Value Proposition Dev. Payer Contracting Outreach
6-K
EX-99.2
a2oykqdoz5e3j
3 Jul 23
NLS Pharmaceutics Releases the Results from its Annual General Meeting
1:22pm
6-K
EX-99.1
xcew46jsmq iu587
8 May 23
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
8:30am
6-K
nrkmo
8 May 23
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
8:30am
6-K
EX-99.1
8dulcilhaj kfq10h9m
22 Dec 22
NLS Pharmaceutics CEO Issues Letter to Shareholders
9:40am
F-3
hnt73p
6 Dec 22
Shelf registration (foreign)
4:41pm
6-K
EX-99.1
aj3qyg0k6k m2redq
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
st3h5wu
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
F-1
meuoxtsff9m 6z
10 Jun 22
Registration statement (foreign)
4:43pm
6-K
EX-99.1
44xy9aae0y4bgdt
6 Jun 22
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
8:02am
6-K
8b3wqqgj8qt2vazs
6 Jun 22
NLS Pharmaceutics Appoints Chad C. Hellmann as Chief Financial Officer
8:02am
424B5
17lye a3dgw9y095h
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-99.1
yocakomh
28 Mar 22
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
8:31am
424B5
8bt97
4 Mar 22
Prospectus supplement for primary offering
4:01pm